SIGN UP

Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)

January 24, 2023 03:52 PM EST

J&J reiterates 2025 sales goal despite looming Stelara exclusivity loss, global economic challenges

Paul Schloesser

Associate Editor

Johnson & Johnson is doubling down on a mid-decade pharma sales goal, and it’s plotting a way even as it loses exclusivity on one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

sponsored

Are programs with compounded GLP-1s safe for your population?